CardioMEMS guided heart failure management in cardio-oncology patients: a tertiary care cancer center experience
Abstract Aims Cancer patients and survivors are at increased risk of developing heart failure (HF) and heart failure hospitalization (HFH). Yet, the utilization of wireless pulmonary artery pressure sensing devices (PAPSD), like CardioMEMS, in this group is limited. Objectives We aimed to explore th...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | Cardio-Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40959-025-00355-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849389125825724416 |
|---|---|
| author | Abdelrahman Ali Maximillian Bourdillon Hyeon-Ju Ryoo Ali Juhee Song Efstratios Koutroumpakis Poonam Jewani Shaden Khalaf Ihab Hamzeh Salil Kumar Nicolas L. Palaskas Jean-Bernard Durand Cezar Iliescu |
| author_facet | Abdelrahman Ali Maximillian Bourdillon Hyeon-Ju Ryoo Ali Juhee Song Efstratios Koutroumpakis Poonam Jewani Shaden Khalaf Ihab Hamzeh Salil Kumar Nicolas L. Palaskas Jean-Bernard Durand Cezar Iliescu |
| author_sort | Abdelrahman Ali |
| collection | DOAJ |
| description | Abstract Aims Cancer patients and survivors are at increased risk of developing heart failure (HF) and heart failure hospitalization (HFH). Yet, the utilization of wireless pulmonary artery pressure sensing devices (PAPSD), like CardioMEMS, in this group is limited. Objectives We aimed to explore the utilization of CardioMEMS in managing HF among oncology patients. Methods We conducted a single-center retrospective study reviewing consecutive patients implanted with the CardioMEMS device between November 11, 2015, and February 21, 2023. We analyzed the device's impact on pulmonary artery pressures and HFH using statistical methods including Cox regression models and correlation studies between NT-proBNP levels and hemodynamic parameters. Results The study included 28 patients, with hypertension (78%) and hyperlipidemia (78%) as prevalent comorbidities. Most patients had heart failure with preserved ejection fraction (64%). Post-implantation, we observed a reduction in HFH and improvements in pulmonary artery pressures. Cox regression identified prior HFH and elevated pulmonary artery systolic (PAS) and diastolic pressures (PAD) as risk factors for repeat HFH (HR: 1.24, 1.04, 1.07, respectively). Biomarker analysis showed a moderate positive correlation between NT-proBNP and PAD, indicating that higher levels are associated with increased hospital admissions. The device was safe with no sensor failures reported. Conclusions CardioMEMS shows potential in improving HF management in cancer patients, reducing HFH and enhancing pulmonary artery pressure profiles. These preliminary results advocate for further, larger-scale prospective studies to confirm the benefits and integrate CardioMEMS into cardio-oncology care. Graphical Abstract |
| format | Article |
| id | doaj-art-6cce26418eff4e5badd8b131a6f45938 |
| institution | Kabale University |
| issn | 2057-3804 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | BMC |
| record_format | Article |
| series | Cardio-Oncology |
| spelling | doaj-art-6cce26418eff4e5badd8b131a6f459382025-08-20T03:42:03ZengBMCCardio-Oncology2057-38042025-07-0111111110.1186/s40959-025-00355-0CardioMEMS guided heart failure management in cardio-oncology patients: a tertiary care cancer center experienceAbdelrahman Ali0Maximillian Bourdillon1Hyeon-Ju Ryoo Ali2Juhee Song3Efstratios Koutroumpakis4Poonam Jewani5Shaden Khalaf6Ihab Hamzeh7Salil Kumar8Nicolas L. Palaskas9Jean-Bernard Durand10Cezar Iliescu11Department of Cardiology, Division of Internal Medicine, The University of Texas MD Anderson Cancer CenterDivision of Cardiology, Department of Internal Medicine, McGovern Medical SchoolDepartment of Cardiology, Division of Internal Medicine, The University of Texas MD Anderson Cancer CenterDepartment of Biostatistics, The University of Texas MD Anderson Cancer CenterDepartment of Cardiology, Division of Internal Medicine, The University of Texas MD Anderson Cancer CenterDepartment of Cardiology, Division of Internal Medicine, The University of Texas MD Anderson Cancer CenterDepartment of Cardiology, Division of Internal Medicine, The University of Texas MD Anderson Cancer CenterDepartment of Cardiology, Division of Internal Medicine, The University of Texas MD Anderson Cancer CenterDepartment of Cardiology, Division of Internal Medicine, The University of Texas MD Anderson Cancer CenterDepartment of Cardiology, Division of Internal Medicine, The University of Texas MD Anderson Cancer CenterDepartment of Cardiology, Division of Internal Medicine, The University of Texas MD Anderson Cancer CenterDepartment of Cardiology, Division of Internal Medicine, The University of Texas MD Anderson Cancer CenterAbstract Aims Cancer patients and survivors are at increased risk of developing heart failure (HF) and heart failure hospitalization (HFH). Yet, the utilization of wireless pulmonary artery pressure sensing devices (PAPSD), like CardioMEMS, in this group is limited. Objectives We aimed to explore the utilization of CardioMEMS in managing HF among oncology patients. Methods We conducted a single-center retrospective study reviewing consecutive patients implanted with the CardioMEMS device between November 11, 2015, and February 21, 2023. We analyzed the device's impact on pulmonary artery pressures and HFH using statistical methods including Cox regression models and correlation studies between NT-proBNP levels and hemodynamic parameters. Results The study included 28 patients, with hypertension (78%) and hyperlipidemia (78%) as prevalent comorbidities. Most patients had heart failure with preserved ejection fraction (64%). Post-implantation, we observed a reduction in HFH and improvements in pulmonary artery pressures. Cox regression identified prior HFH and elevated pulmonary artery systolic (PAS) and diastolic pressures (PAD) as risk factors for repeat HFH (HR: 1.24, 1.04, 1.07, respectively). Biomarker analysis showed a moderate positive correlation between NT-proBNP and PAD, indicating that higher levels are associated with increased hospital admissions. The device was safe with no sensor failures reported. Conclusions CardioMEMS shows potential in improving HF management in cancer patients, reducing HFH and enhancing pulmonary artery pressure profiles. These preliminary results advocate for further, larger-scale prospective studies to confirm the benefits and integrate CardioMEMS into cardio-oncology care. Graphical Abstracthttps://doi.org/10.1186/s40959-025-00355-0CardioMEMSPulmonary artery pressure sensing devicesHeart failureCardio-oncology |
| spellingShingle | Abdelrahman Ali Maximillian Bourdillon Hyeon-Ju Ryoo Ali Juhee Song Efstratios Koutroumpakis Poonam Jewani Shaden Khalaf Ihab Hamzeh Salil Kumar Nicolas L. Palaskas Jean-Bernard Durand Cezar Iliescu CardioMEMS guided heart failure management in cardio-oncology patients: a tertiary care cancer center experience Cardio-Oncology CardioMEMS Pulmonary artery pressure sensing devices Heart failure Cardio-oncology |
| title | CardioMEMS guided heart failure management in cardio-oncology patients: a tertiary care cancer center experience |
| title_full | CardioMEMS guided heart failure management in cardio-oncology patients: a tertiary care cancer center experience |
| title_fullStr | CardioMEMS guided heart failure management in cardio-oncology patients: a tertiary care cancer center experience |
| title_full_unstemmed | CardioMEMS guided heart failure management in cardio-oncology patients: a tertiary care cancer center experience |
| title_short | CardioMEMS guided heart failure management in cardio-oncology patients: a tertiary care cancer center experience |
| title_sort | cardiomems guided heart failure management in cardio oncology patients a tertiary care cancer center experience |
| topic | CardioMEMS Pulmonary artery pressure sensing devices Heart failure Cardio-oncology |
| url | https://doi.org/10.1186/s40959-025-00355-0 |
| work_keys_str_mv | AT abdelrahmanali cardiomemsguidedheartfailuremanagementincardiooncologypatientsatertiarycarecancercenterexperience AT maximillianbourdillon cardiomemsguidedheartfailuremanagementincardiooncologypatientsatertiarycarecancercenterexperience AT hyeonjuryooali cardiomemsguidedheartfailuremanagementincardiooncologypatientsatertiarycarecancercenterexperience AT juheesong cardiomemsguidedheartfailuremanagementincardiooncologypatientsatertiarycarecancercenterexperience AT efstratioskoutroumpakis cardiomemsguidedheartfailuremanagementincardiooncologypatientsatertiarycarecancercenterexperience AT poonamjewani cardiomemsguidedheartfailuremanagementincardiooncologypatientsatertiarycarecancercenterexperience AT shadenkhalaf cardiomemsguidedheartfailuremanagementincardiooncologypatientsatertiarycarecancercenterexperience AT ihabhamzeh cardiomemsguidedheartfailuremanagementincardiooncologypatientsatertiarycarecancercenterexperience AT salilkumar cardiomemsguidedheartfailuremanagementincardiooncologypatientsatertiarycarecancercenterexperience AT nicolaslpalaskas cardiomemsguidedheartfailuremanagementincardiooncologypatientsatertiarycarecancercenterexperience AT jeanbernarddurand cardiomemsguidedheartfailuremanagementincardiooncologypatientsatertiarycarecancercenterexperience AT cezariliescu cardiomemsguidedheartfailuremanagementincardiooncologypatientsatertiarycarecancercenterexperience |